skip to navigation

Emmett Cunningham

Prof. Dr. Emmett Cunningham MD, PhD

Profession:
Ophthalmologist
Job Title:
Partner
Medical School:
Johns Hopkins University
Residency Program:
UCSF
Location:
Hillsborough, United States
Contact Information:
195 Rizal Drive
Hillsborough, California
United States 94010
Phone: 650 238 5014
Fax: 650 238 5001
Email: emmett_cunningham@yahoo.com
Web site: www.clarusventures.com

Dr. Cunningham is a Partner at Clarus Ventures. Prior to Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc., where he helped build and lead the team that developed and commercialized Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc, where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology.
Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 250 publications. He is Director of the Uveitis Service at California Pacific Medical Center, an Adjunct Clinical Professor of Ophthalmology at Stanford University, was Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001. Dr. Cunningham received an M.D. and M.P.H. in epidemiology and statistics from Johns Hopkins University, a PhD in neuroscience from the University of California at San Diego (UCSD) for work done at The Salk Institute, and completed both a residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at The Francis I. Proctor Foundation, UCSF.
Dr. Cunningham is a member of the Board of Directors of both SARCode, Inc. and Neomend, Inc., and a Board observer for Zogenix, Inc., Pearl Therapeutics, Taligen Therapeutics, Ophthotech Corporation, and Ferrokin Biosciences.

Stay connected:         Follow us on Instagram

Web site design and web development by D3 Solutions